Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 118

1.

The effect of the EP3 antagonist DG-041 on male mice with diet-induced obesity.

Ceddia RP, Downey JD, Morrison RD, Kraemer MP, Davis SE, Wu J, Lindsley CW, Yin H, Daniels JS, Breyer RM.

Prostaglandins Other Lipid Mediat. 2019 Jul 2;144:106353. doi: 10.1016/j.prostaglandins.2019.106353. [Epub ahead of print]

PMID:
31276827
2.

The cyclooxygenase-1/mPGES-1/endothelial prostaglandin EP4 receptor pathway constrains myocardial ischemia-reperfusion injury.

Zhu L, Xu C, Huo X, Hao H, Wan Q, Chen H, Zhang X, Breyer RM, Huang Y, Cao X, Liu DP, FitzGerald GA, Wang M.

Nat Commun. 2019 Apr 23;10(1):1888. doi: 10.1038/s41467-019-09492-4.

3.

Protective Role of mPGES-1 (Microsomal Prostaglandin E Synthase-1)-Derived PGE2 (Prostaglandin E2) and the Endothelial EP4 (Prostaglandin E Receptor) in Vascular Responses to Injury.

Hao H, Hu S, Wan Q, Xu C, Chen H, Zhu L, Xu Z, Meng J, Breyer RM, Li N, Liu DP, FitzGerald GA, Wang M.

Arterioscler Thromb Vasc Biol. 2018 May;38(5):1115-1124. doi: 10.1161/ATVBAHA.118.310713. Epub 2018 Mar 29.

4.

Prostaglandin E2 stimulates adaptive IL-22 production and promotes allergic contact dermatitis.

Robb CT, McSorley HJ, Lee J, Aoki T, Yu C, Crittenden S, Astier A, Felton JM, Parkinson N, Ayele A, Breyer RM, Anderton SM, Narumiya S, Rossi AG, Howie SE, Guttman-Yassky E, Weller RB, Yao C.

J Allergy Clin Immunol. 2018 Jan;141(1):152-162. doi: 10.1016/j.jaci.2017.04.045. Epub 2017 Jun 3.

5.

Opposing effects of prostaglandin E2 receptors EP3 and EP4 on mouse and human β-cell survival and proliferation.

Carboneau BA, Allan JA, Townsend SE, Kimple ME, Breyer RM, Gannon M.

Mol Metab. 2017 Apr 5;6(6):548-559. doi: 10.1016/j.molmet.2017.04.002. eCollection 2017 Jun.

6.

Niacin ameliorates ulcerative colitis via prostaglandin D2-mediated D prostanoid receptor 1 activation.

Li J, Kong D, Wang Q, Wu W, Tang Y, Bai T, Guo L, Wei L, Zhang Q, Yu Y, Qian Y, Zuo S, Liu G, Liu Q, Wu S, Zang Y, Zhu Q, Jia D, Wang Y, Yao W, Ji Y, Yin H, Nakamura M, Lazarus M, Breyer RM, Wang L, Yu Y.

EMBO Mol Med. 2017 May;9(5):571-588. doi: 10.15252/emmm.201606987.

7.

Regulation of pancreatic β-cell function and mass dynamics by prostaglandin signaling.

Carboneau BA, Breyer RM, Gannon M.

J Cell Commun Signal. 2017 Jun;11(2):105-116. doi: 10.1007/s12079-017-0377-7. Epub 2017 Jan 28. Review.

8.

Niacin Promotes Cardiac Healing after Myocardial Infarction through Activation of the Myeloid Prostaglandin D2 Receptor Subtype 1.

Kong D, Li J, Shen Y, Liu G, Zuo S, Tao B, Ji Y, Lu A, Lazarus M, Breyer RM, Yu Y.

J Pharmacol Exp Ther. 2017 Mar;360(3):435-444. doi: 10.1124/jpet.116.238261. Epub 2017 Jan 5.

9.

PKA regulatory IIα subunit is essential for PGD2-mediated resolution of inflammation.

Kong D, Shen Y, Liu G, Zuo S, Ji Y, Lu A, Nakamura M, Lazarus M, Stratakis CA, Breyer RM, Yu Y.

J Exp Med. 2016 Sep 19;213(10):2209-26. doi: 10.1084/jem.20160459. Epub 2016 Sep 12.

10.

Prostaglandin E2 receptor EP3 regulates both adipogenesis and lipolysis in mouse white adipose tissue.

Xu H, Fu JL, Miao YF, Wang CJ, Han QF, Li S, Huang SZ, Du SN, Qiu YX, Yang JC, Gustafsson JÅ, Breyer RM, Zheng F, Wang NP, Zhang XY, Guan YF.

J Mol Cell Biol. 2016 Dec;8(6):518-529. Epub 2016 Jul 19.

11.

Myeloid Cell Prostaglandin E2 Receptor EP4 Modulates Cytokine Production but Not Atherogenesis in a Mouse Model of Type 1 Diabetes.

Vallerie SN, Kramer F, Barnhart S, Kanter JE, Breyer RM, Andreasson KI, Bornfeldt KE.

PLoS One. 2016 Jun 28;11(6):e0158316. doi: 10.1371/journal.pone.0158316. eCollection 2016.

12.

Regulation of arterial reactivity by concurrent signaling through the E-prostanoid receptor 3 and angiotensin receptor 1.

Kraemer MP, Choi H, Reese J, Lamb FS, Breyer RM.

Vascul Pharmacol. 2016 Sep;84:47-54. doi: 10.1016/j.vph.2016.05.015. Epub 2016 May 31.

13.

Knockout of the Prostaglandin E2 Receptor Subtype 3 Promotes Eccentric Cardiac Hypertrophy and Fibrosis in Mice.

Liu S, Ji Y, Yao J, Zhao X, Xu H, Guan Y, Breyer RM, Sheng H, Zhu J.

J Cardiovasc Pharmacol Ther. 2017 Jan;22(1):71-82. doi: 10.1177/1074248416642520. Epub 2016 Jun 23.

PMID:
27093953
14.

Prostaglandin E₂ constrains systemic inflammation through an innate lymphoid cell-IL-22 axis.

Duffin R, O'Connor RA, Crittenden S, Forster T, Yu C, Zheng X, Smyth D, Robb CT, Rossi F, Skouras C, Tang S, Richards J, Pellicoro A, Weller RB, Breyer RM, Mole DJ, Iredale JP, Anderton SM, Narumiya S, Maizels RM, Ghazal P, Howie SE, Rossi AG, Yao C.

Science. 2016 Mar 18;351(6279):1333-8. doi: 10.1126/science.aad9903.

15.

The PGE2 EP3 Receptor Regulates Diet-Induced Adiposity in Male Mice.

Ceddia RP, Lee D, Maulis MF, Carboneau BA, Threadgill DW, Poffenberger G, Milne G, Boyd KL, Powers AC, McGuinness OP, Gannon M, Breyer RM.

Endocrinology. 2016 Jan;157(1):220-32. doi: 10.1210/en.2015-1693. Epub 2015 Oct 20.

16.

EP3 receptor deficiency attenuates pulmonary hypertension through suppression of Rho/TGF-β1 signaling.

Lu A, Zuo C, He Y, Chen G, Piao L, Zhang J, Xiao B, Shen Y, Tang J, Kong D, Alberti S, Chen D, Zuo S, Zhang Q, Yan S, Fei X, Yuan F, Zhou B, Duan S, Yu Y, Lazarus M, Su Y, Breyer RM, Funk CD, Yu Y.

J Clin Invest. 2015 Mar 2;125(3):1228-42. doi: 10.1172/JCI77656. Epub 2015 Feb 9.

17.

Cyclooxygenase-2-derived prostaglandin E₂ promotes injury-induced vascular neointimal hyperplasia through the E-prostanoid 3 receptor.

Zhang J, Zou F, Tang J, Zhang Q, Gong Y, Wang Q, Shen Y, Xiong L, Breyer RM, Lazarus M, Funk CD, Yu Y.

Circ Res. 2013 Jul 5;113(2):104-14. doi: 10.1161/CIRCRESAHA.113.301033. Epub 2013 Apr 17.

18.

Differential stem- and progenitor-cell trafficking by prostaglandin E2.

Hoggatt J, Mohammad KS, Singh P, Hoggatt AF, Chitteti BR, Speth JM, Hu P, Poteat BA, Stilger KN, Ferraro F, Silberstein L, Wong FK, Farag SS, Czader M, Milne GL, Breyer RM, Serezani CH, Scadden DT, Guise TA, Srour EF, Pelus LM.

Nature. 2013 Mar 21;495(7441):365-9. doi: 10.1038/nature11929. Epub 2013 Mar 13.

19.

Correction to CHOBIMALT: A Cholesterol-Based Detergent.

Howell SC, Fraser NJ, Mittal R, Huang L, Travis B, Breyer RM, Sanders CR.

Biochemistry. 2013 Jan 15;52(2):445. doi: 10.1021/bi3017203. Epub 2013 Jan 4. No abstract available.

20.

Development of an in vivo active, dual EP1 and EP3 selective antagonist based on a novel acyl sulfonamide bioisostere.

Downey JD, Saleh SA, Bridges TM, Morrison RD, Daniels JS, Lindsley CW, Breyer RM.

Bioorg Med Chem Lett. 2013 Jan 1;23(1):37-41. doi: 10.1016/j.bmcl.2012.11.046. Epub 2012 Nov 24. Erratum in: Bioorg Med Chem Lett. 2013 Dec 15;23(24):6939.

21.

Extracellular loop II modulates GTP sensitivity of the prostaglandin EP3 receptor.

Natarajan C, Hata AN, Hamm HE, Zent R, Breyer RM.

Mol Pharmacol. 2013 Jan;83(1):206-16. doi: 10.1124/mol.112.080473. Epub 2012 Oct 18.

22.

Inactivation of the E-prostanoid 3 receptor attenuates the angiotensin II pressor response via decreasing arterial contractility.

Chen L, Miao Y, Zhang Y, Dou D, Liu L, Tian X, Yang G, Pu D, Zhang X, Kang J, Gao Y, Wang S, Breyer MD, Wang N, Zhu Y, Huang Y, Breyer RM, Guan Y.

Arterioscler Thromb Vasc Biol. 2012 Dec;32(12):3024-32. doi: 10.1161/ATVBAHA.112.254052. Epub 2012 Oct 11.

23.

EP1 disruption attenuates end-organ damage in a mouse model of hypertension.

Bartlett CS, Boyd KL, Harris RC, Zent R, Breyer RM.

Hypertension. 2012 Nov;60(5):1184-91. doi: 10.1161/HYPERTENSIONAHA.112.199026. Epub 2012 Sep 24. Erratum in: Hypertension. 2013 Dec;62(6):e48.

24.

Inflammatory prostaglandin E2 signaling in a mouse model of Alzheimer disease.

Shi J, Wang Q, Johansson JU, Liang X, Woodling NS, Priyam P, Loui TM, Merchant M, Breyer RM, Montine TJ, Andreasson K.

Ann Neurol. 2012 Nov;72(5):788-98. doi: 10.1002/ana.23677. Epub 2012 Aug 22.

25.

Prostaglandin I2 signaling drives Th17 differentiation and exacerbates experimental autoimmune encephalomyelitis.

Zhou W, Dowell DR, Huckabee MM, Newcomb DC, Boswell MG, Goleniewska K, Lotz MT, Toki S, Yin H, Yao S, Natarajan C, Wu P, Sriram S, Breyer RM, Fitzgerald GA, Peebles RS Jr.

PLoS One. 2012;7(5):e33518. doi: 10.1371/journal.pone.0033518. Epub 2012 May 10.

26.

Eicosanoid receptor subtype-mediated opposing regulation of TLR-stimulated expression of astrocyte glial-derived neurotrophic factor.

Li X, Cudaback E, Breyer RM, Montine KS, Keene CD, Montine TJ.

FASEB J. 2012 Jul;26(7):3075-83. doi: 10.1096/fj.11-200279. Epub 2012 Apr 12.

27.

Prostaglandin E2-mediated attenuation of mesocortical dopaminergic pathway is critical for susceptibility to repeated social defeat stress in mice.

Tanaka K, Furuyashiki T, Kitaoka S, Senzai Y, Imoto Y, Segi-Nishida E, Deguchi Y, Breyer RM, Breyer MD, Narumiya S.

J Neurosci. 2012 Mar 21;32(12):4319-29. doi: 10.1523/JNEUROSCI.5952-11.2012.

28.

Blockade of prostaglandin E2 signaling through EP1 and EP3 receptors attenuates Flt3L-dependent dendritic cell development from hematopoietic progenitor cells.

Singh P, Hoggatt J, Hu P, Speth JM, Fukuda S, Breyer RM, Pelus LM.

Blood. 2012 Feb 16;119(7):1671-82. doi: 10.1182/blood-2011-03-342428. Epub 2011 Nov 22.

29.

Prostaglandin E2 modulation of blood pressure homeostasis: studies in rodent models.

Swan CE, Breyer RM.

Prostaglandins Other Lipid Mediat. 2011 Nov;96(1-4):10-3. doi: 10.1016/j.prostaglandins.2011.07.001. Epub 2011 Jul 27. Review.

30.

Regulation of calcium channels and exocytosis in mouse adrenal chromaffin cells by prostaglandin EP3 receptors.

Jewell ML, Breyer RM, Currie KP.

Mol Pharmacol. 2011 Jun;79(6):987-96. doi: 10.1124/mol.110.068569. Epub 2011 Mar 7.

31.

Suppressed microglial E prostanoid receptor 1 signaling selectively reduces tumor necrosis factor alpha and interleukin 6 secretion from toll-like receptor 3 activation.

Li X, Cudaback E, Keene CD, Breyer RM, Montine TJ.

Glia. 2011 Apr;59(4):569-76. doi: 10.1002/glia.21125. Epub 2011 Jan 6.

32.

Evidence for the presence of a critical disulfide bond in the mouse EP3γ receptor.

Downey JD, Sanders CR, Breyer RM.

Prostaglandins Other Lipid Mediat. 2011 Feb;94(1-2):53-8. doi: 10.1016/j.prostaglandins.2010.12.007. Epub 2011 Jan 12.

33.

CHOBIMALT: a cholesterol-based detergent.

Howell SC, Mittal R, Huang L, Travis B, Breyer RM, Sanders CR.

Biochemistry. 2010 Nov 9;49(44):9572-83. doi: 10.1021/bi101334j. Erratum in: Biochemistry. 2013 Jan 15;52(2):445.

34.

Suppressed accumulation of cerebral amyloid {beta} peptides in aged transgenic Alzheimer's disease mice by transplantation with wild-type or prostaglandin E2 receptor subtype 2-null bone marrow.

Keene CD, Chang RC, Lopez-Yglesias AH, Shalloway BR, Sokal I, Li X, Reed PJ, Keene LM, Montine KS, Breyer RM, Rockhill JK, Montine TJ.

Am J Pathol. 2010 Jul;177(1):346-54. doi: 10.2353/ajpath.2010.090840. Epub 2010 Jun 3.

35.

PGE2 decreases reactivity of human platelets by activating EP2 and EP4.

Smith JP, Haddad EV, Downey JD, Breyer RM, Boutaud O.

Thromb Res. 2010 Jul;126(1):e23-9. doi: 10.1016/j.thromres.2010.04.003. Epub 2010 May 8.

36.

Impaired cognition, sensorimotor gating, and hippocampal long-term depression in mice lacking the prostaglandin E2 EP2 receptor.

Savonenko A, Munoz P, Melnikova T, Wang Q, Liang X, Breyer RM, Montine TJ, Kirkwood A, Andreasson K.

Exp Neurol. 2009 May;217(1):63-73. doi: 10.1016/j.expneurol.2009.01.016. Epub 2009 Feb 3.

37.

Protection of hippocampal neurogenesis from toll-like receptor 4-dependent innate immune activation by ablation of prostaglandin E2 receptor subtype EP1 or EP2.

Keene CD, Chang R, Stephen C, Nivison M, Nutt SE, Look A, Breyer RM, Horner PJ, Hevner R, Montine TJ.

Am J Pathol. 2009 Jun;174(6):2300-9. doi: 10.2353/ajpath.2009.081153. Epub 2009 Apr 23.

38.

Macrophage EP4 deficiency increases apoptosis and suppresses early atherosclerosis.

Babaev VR, Chew JD, Ding L, Davis S, Breyer MD, Breyer RM, Oates JA, Fazio S, Linton MF.

Cell Metab. 2008 Dec;8(6):492-501. doi: 10.1016/j.cmet.2008.09.005.

39.

Altered hippocampal long-term synaptic plasticity in mice deficient in the PGE2 EP2 receptor.

Yang H, Zhang J, Breyer RM, Chen C.

J Neurochem. 2009 Jan;108(1):295-304. doi: 10.1111/j.1471-4159.2008.05766.x. Epub 2008 Nov 21.

40.

The prostaglandin E2 EP2 receptor accelerates disease progression and inflammation in a model of amyotrophic lateral sclerosis.

Liang X, Wang Q, Shi J, Lokteva L, Breyer RM, Montine TJ, Andreasson K.

Ann Neurol. 2008 Sep;64(3):304-14. doi: 10.1002/ana.21437.

41.

Therapeutic targets in prostaglandin E2 signaling for neurologic disease.

Cimino PJ, Keene CD, Breyer RM, Montine KS, Montine TJ.

Curr Med Chem. 2008;15(19):1863-9. Review.

42.

Increased dietary NaCl induces renal medullary PGE2 production and natriuresis via the EP2 receptor.

Chen J, Zhao M, He W, Milne GL, Howard JR, Morrow J, Hébert RL, Breyer RM, Chen J, Hao CM.

Am J Physiol Renal Physiol. 2008 Sep;295(3):F818-25. doi: 10.1152/ajprenal.90253.2008. Epub 2008 Jul 16.

43.

Misoprostol, an anti-ulcer agent and PGE2 receptor agonist, protects against cerebral ischemia.

Li J, Liang X, Wang Q, Breyer RM, McCullough L, Andreasson K.

Neurosci Lett. 2008 Jun 20;438(2):210-5. doi: 10.1016/j.neulet.2008.04.054. Epub 2008 Apr 20.

44.

Mouse EP3 alpha, beta, and gamma receptor variants reduce tumor cell proliferation and tumorigenesis in vivo.

Macias-Perez IM, Zent R, Carmosino M, Breyer MD, Breyer RM, Pozzi A.

J Biol Chem. 2008 May 2;283(18):12538-45. doi: 10.1074/jbc.M800105200. Epub 2008 Jan 29.

45.

Antihypertensive effects of selective prostaglandin E2 receptor subtype 1 targeting.

Guan Y, Zhang Y, Wu J, Qi Z, Yang G, Dou D, Gao Y, Chen L, Zhang X, Davis LS, Wei M, Fan X, Carmosino M, Hao C, Imig JD, Breyer RM, Breyer MD.

J Clin Invest. 2007 Sep;117(9):2496-505.

46.

Bacterial clearance of Pseudomonas aeruginosa is enhanced by the inhibition of COX-2.

Sadikot RT, Zeng H, Azim AC, Joo M, Dey SK, Breyer RM, Peebles RS, Blackwell TS, Christman JW.

Eur J Immunol. 2007 Apr;37(4):1001-9.

47.

Prostaglandin I2 analogs inhibit Th1 and Th2 effector cytokine production by CD4 T cells.

Zhou W, Blackwell TS, Goleniewska K, O'Neal JF, Fitzgerald GA, Lucitt M, Breyer RM, Peebles RS Jr.

J Leukoc Biol. 2007 Mar;81(3):809-17. Epub 2006 Nov 29.

PMID:
17135575
48.

Deletion of prostaglandin E2 EP2 receptor protects against ultraviolet-induced carcinogenesis, but increases tumor aggressiveness.

Brouxhon S, Konger RL, VanBuskirk J, Sheu TJ, Ryan J, Erdle B, Almudevar A, Breyer RM, Scott G, Pentland AP.

J Invest Dermatol. 2007 Feb;127(2):439-46. Epub 2006 Sep 14.

49.

Prostaglandin E2 receptor subtype 2 (EP2) null mice are protected against murine lung tumorigenesis.

Keith RL, Geraci MW, Nana-Sinkam SP, Breyer RM, Hudish TM, Meyer AM, Malkinson AM, Dwyer-Nield LD.

Anticancer Res. 2006 Jul-Aug;26(4B):2857-61.

50.

EP2, a receptor for PGE2, regulates tumor angiogenesis through direct effects on endothelial cell motility and survival.

Kamiyama M, Pozzi A, Yang L, DeBusk LM, Breyer RM, Lin PC.

Oncogene. 2006 Nov 9;25(53):7019-28. Epub 2006 May 29.

PMID:
16732324

Supplemental Content

Loading ...
Support Center